PLRX — PLIANT THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1746473 ·
Last close
$0.66
Market Cap
$40.93M
52W High
$1.67
52W Low
$0.65
ADV30
412,869
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -25,742,000 | -24,377,000 | 169,877,000 | 26,568,000 | 43,245,000 |
| Jun 2026 | 0 | — | -23,862,000 | -22,371,000 | 189,881,000 | 24,883,000 | 42,955,000 |
| Mar 2026 | 0 | — | -21,772,000 | -20,040,000 | 202,596,000 | 22,190,000 | 37,430,000 |
| Dec 2025 | 0 | — | -23,577,000 | -23,577,000 | 225,228,000 | 45,445,000 | 44,023,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-70,895,000
Investing CF
$41,079,000
Financing CF
$-32,121,000
CapEx
$-374,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.49
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-901,807,000
Inventory
—
Receivables
$873,000
ST Investments
$133,218,000
EBIT TTM
$-91,338,000
Pretax Income TTM
$-92,289,000
Interest Exp TTM
$951,000
Analysts
1
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -156,373,000 | -149,344,000 | 225,228,000 | 44,023,000 | 181,205,000 | -128,336,000 |
| Dec 2024 | 0 | -228,365,000 | -210,304,000 | 396,949,000 | 92,868,000 | 304,081,000 | -155,503,000 |
| Dec 2023 | 1,580,000 | -184,145,000 | -161,336,000 | 512,154,000 | 38,578,000 | 473,576,000 | -116,361,000 |
| Dec 2022 | 9,685,000 | -127,200,000 | -123,321,000 | 350,613,000 | 37,271,000 | 313,342,000 | -94,631,000 |
TTM Snapshot
Revenues TTM
$117,786,000
NetIncome TTM
$-92,289,000
OpCashFlow TTM
—
Assets (Latest)
$189,881,000
Forward EPS
$-1.29
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DWTX | Dogwood Therapeutics, Inc. | $41.29M | $1.08 | — |
| ELTX | Elicio Therapeutics, Inc. | $40.48M | $1.43 | — |
| TLPH | TALPHERA, INC. | $41.61M | $0.80 | — |
| ALDX | Aldeyra Therapeutics, Inc. | $41.88M | $0.69 | — |
| ATNM | Actinium Pharmaceuticals, Inc. | $42.45M | $1.35 | — |
News headlines (Yahoo Finance, 1h cache)
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
2026-11-12 21:05 · Yahoo
Pliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer
2026-11-09 13:30 · Yahoo
Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer
2026-10-29 20:05 · Yahoo
Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA)
2026-10-20 12:30 · Yahoo
Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026
2026-10-19 20:05 · Yahoo
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
2026-09-30 20:10 · Yahoo
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
2026-08-18 12:30 · Yahoo
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
2026-08-11 20:05 · Yahoo
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors
2026-07-13 12:30 · Yahoo
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
2026-05-06 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.